Nuformix files first patent for novel cannabinoid cocrystals
Abraham Darwyne
Company News - 2 min read
09:02, 9th September 2019

Nuformix (NFX) FOLLOW files first patent for novel cannabinoid cocrystals

The patent comes after the start of development activities as part of the Strategic Cannabinoid Agreement with Ebers Tech Inc.

The patented cannabinoid forms have immediate applications in both pharmaceutical and consumer products worldwide, the company said.

The number of patents filed is one of several key performance indicators for the collaboration, which generate milestone payments for Nuformix, in addition to 20% of royalties.

Ebers has exclusive rights to technology Nuformix patents for the development of differentiated cannabinoid products.

Shares in Nuformix were trading 5% higher on Monday following the filing

Cannabinoid products continue to attract more scientific interest as its therapeutic promise becomes increasingly validated.

Nigel Little, Director of Ebers said: “From a strategic perspective, Nuformix's proven track-record in securing worldwide patent protection for improved drug forms provides Ebers with an opportunity to generate high-value IP, identified as a limitation within the emerging cannabinoid market.”

Ebers Tech Inc. is a private Canadian cannabinoid development company backed by leaders from the financial sector with connections to major vertically integrated US cannabinoid players.

Dr. Dan Gooding CEO of Nuformix said that the IP filing was the “first disclosable validation of the Ebers agreement”. He added that the patent filing creates a path to further income from Ebers, and that the company will inform the market as further patents are filed and milestone and royalties are paid.

Follow News & Updates from Nuformix here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist